---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-077083"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2022-07-05T23:59:59+00:00"
generated_at: "2026-06-24T21:10:39.282350+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eloxx Pharmaceuticals appoints Lindsay Androski to board; five directors resign, board shrinks from nine to five

## Summary
- Five directors (Gadi Veinrib, Ran Nussbaum, Zafrira Avnur, Rajesh Parekh, Jasbir Seehra) resign effective July 1, 2022.
- Board size reduced from nine to five directors; Alan Walts and Tomer Kariv appointed as committee chairs.
- Lindsay Androski appointed to fill vacancy, joining Audit and Compensation Committees.
- Androski is President/CEO of Roivant Social Ventures and was part of founding team at Roivant Sciences.
- Company states resignations not due to any disagreement; aims for a 'nimble and focused' board.

## SEC filing metadata
- accession: 0001104659-22-077083
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2022-07-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465922077083/0001104659-22-077083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465922077083/tm2219962d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-077083
- JSON: https://secwatch.observer/filing/0001104659-22-077083.json
- Plain text: https://secwatch.observer/filing/0001104659-22-077083.txt

## Key facts
- Executive change
  Gadi Veinrib resigned as Director at Eloxx Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: On June 30, 2022, each of Zafrira Avnur, Rajesh Parekh and Gadi Veinrib notified the Board of their respective resignations from the Board and the respective committees of the Board on which they serve.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465922077083/0001104659-22-077083-index.htm
- Executive change
  Zafrira Avnur resigned as Director at Eloxx Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: On June 30, 2022, each of Zafrira Avnur, Rajesh Parekh and Gadi Veinrib notified the Board of their respective resignations from the Board and the respective committees of the Board on which they serve.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465922077083/0001104659-22-077083-index.htm
- Executive change
  Rajesh Parekh resigned as Director at Eloxx Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: On June 30, 2022, each of Zafrira Avnur, Rajesh Parekh and Gadi Veinrib notified the Board of their respective resignations from the Board and the respective committees of the Board on which they serve.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465922077083/0001104659-22-077083-index.htm
- Executive change
  Jasbir Seehra resigned as Director at Eloxx Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: On June 28, 2022, each of Ran Nussbaum and Jasbir Seehra notified the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) of their respective resignations from the Board and the respective committees of the Board on which they serve.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465922077083/0001104659-22-077083-index.htm
- Executive change
  Ran Nussbaum resigned as Director at Eloxx Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: On June 28, 2022, each of Ran Nussbaum and Jasbir Seehra notified the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) of their respective resignations from the Board and the respective committees of the Board on which they serve.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465922077083/0001104659-22-077083-index.htm
- Executive change
  Lindsay Androski was appointed as Director at Eloxx Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: On June 30, 2022, the Board appointed Lindsay Androski to serve as a director on the Company’s Board to fill the remaining vacancy and as a member of the Board’s Audit Committee and Compensation Committee, in each case, effective as of the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465922077083/0001104659-22-077083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.